MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of American Depositary Shares (“ADSs”) representing its ordinary shares in the United States (“U.S.”) and listing on the Nasdaq Global Market (“Nasdaq”). Telix’s ordinary shares will remain listed on the Australian Securities Exchange.
The number of ADSs that will likely be offered, the number of underlying common shares that will potentially be issued, the value of such tools, and the timing of the offering are yet to be defined. Telix ADSs to be sold in connection with the proposed offering are expected to file with the U. S. Securities and Exchange Commission. U. S. Securities and Exchange Commission (“SEC”). No securities will be sold or any offer to buy accepted prior to the time the registration becomes effective and is subject to a review proceeding through the U. S. SEC. U. S. regulatory frameworks, market conditions, investor demand, and standard corporate approvals. No final resolution has been made in connection with the offering or the directory on Nasdaq and there can be no warranty as to the occurrence, timeliness, value and/or final touch of any offering or directory.
This disclosure constitutes an offer to sell or a solicitation of an offer to buy securities. Any offer, solicitation, or offer to buy or sell securities shall be made in accordance with the registration requirements of the U. S. Securities Act. UU. de 1933, as amended (“Securities Act”). This announcement is made pursuant to Rule 135 of the Securities Act.
Telix Investor Relations
AustraliaMs. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: [email protected]
United StatesLisa WilsonInternal CommunicationsEmail: lwilson@insitecony. com
This announcement was made through the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board of Directors.
Legal
This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Except as required by applicable law or regulation, Telix assumes no legal responsibility to publicly update or revise any forward-looking statements. The above functionality cannot be taken as an indication of long-term functionality. Readers read this announcement as well as our curtain risks. , as revealed in our most recent reports filed with the ASX and on our website.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).